[{"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-001", "question": "A 54-year-old man with decompensated alcoholic cirrhosis (MELD-Na 29) is intubated for acute variceal hemorrhage and started on norepinephrine for hemorrhagic shock. Despite volume resuscitation, blood products, and endoscopic band ligation, he requires increasing vasopressor doses. Continuous renal replacement therapy is initiated for worsening azotemia and hyperkalemia. His MAP is 62 mm Hg on norepinephrine 0.24 mcg/kg/min and vasopressin 0.03 units/min. Lactate is 5.1 mmol/L; pH 7.28; ScvO2 76%. Bedside echo shows hyperdynamic LV function, small underfilled LV, and collapsible IVC. CVP is 4 mm Hg. You are considering adding a third agent. Which vasopressor strategy is most appropriate now?", "options": ["Add epinephrine infusion targeting higher MAP (70-75 mm Hg)", "Add low-dose dobutamine to improve splanchnic perfusion", "Add angiotensin II infusion while maintaining current MAP target", "Increase vasopressin above 0.04 units/min to exploit V1 receptor effect", "Switch norepinephrine to phenylephrine to minimize beta-adrenergic effects"], "answer": "C", "answer_index": 2, "explanation": "He has vasodilatory shock in advanced cirrhosis with catecholamine-resistant hypotension despite adequate volume; angiotensin II is reasonable as a third-line agent in catecholamine-refractory vasodilatory shock and has emerging use in hepatorenal-type circulatory failure. Epinephrine would increase lactate and myocardial oxygen demand without addressing RAAS dysregulation; high-dose vasopressin increases ischemia risk, phenylephrine may worsen gut perfusion, and dobutamine is not indicated with hyperdynamic LV and adequate ScvO2.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed. Key stem clues: Advanced cirrhosis with catecholamine-refractory vasodilatory shock, hyperdynamic LV, low CVP, and adequate ScvO2. The most appropriate third-line vasopressor in this scenario, per current critical care and hepatology guidelines, is typically an agent like terlipressin (not listed) or cautious vasopressin uptitration, not angiotensin II, which lacks robust evidence in this specific context and is not standard of care. The keyed answer (C) is not the best-supported option. The most logical choice from the list is D (increase vasopressin), as it is the guideline-recommended agent for hepatorenal syndrome and variceal hemorrhage with refractory shock, exploiting V1 receptor-mediated vasoconstriction. Main medical issue: Angiotensin II is not the standard third-line agent for catecholamine-resistant shock in decompensated cirrhosis. Minimal fix: Change the key to D and adjust the rationale to reflect guideline-based use of vasopressin/terlipressin in hepatorenal syndrome and variceal bleeding.\",\n  \"logical_false_reason\": \"K\",\n  \"logical_validity\": false,\n  \"medical_accuracy_score\":  \"2\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed. Key stem clues: Advanced cirrhosis with catecholamine-refractory vasodilatory shock, hyperdynamic LV, low CVP, and adequate ScvO2. The most appropriate third-line vasopressor in this scenario, per current critical care and hepatology guidelines, is typically an agent like terlipressin (not listed) or cautious vasopressin uptitration, not angiotensin II, which lacks robust evidence in this specific context and is not standard of care. The keyed answer (C) is not the best-supported option. The most logical choice from the list is D (increase vasopressin), as it is the guideline-recommended agent for hepatorenal syndrome and variceal hemorrhage with refractory shock, exploiting V1 receptor-mediated vasoconstriction. Main medical issue: Angiotensin II is not the standard third-line agent for catecholamine-resistant shock in decompensated cirrhosis. Minimal fix: Change the key to D and adjust the rationale to reflect guideline-based use of vasopressin/terlipressin in hepatorenal syndrome and variceal bleeding.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-002", "question": "A 63-year-old woman with a history of JAK2-positive polycythemia vera treated with hydroxyurea for 9 years presents with 3 months of progressive fatigue, 7-kg weight loss, early satiety, and drenching night sweats. Exam shows marked splenomegaly 12 cm below the costal margin. CBC: Hgb 9.1 g/dL, MCV 96 fL, WBC 18,000/µL with left shift, platelets 110,000/µL. Peripheral smear reveals tear-drop cells, nucleated RBCs, and leukoerythroblastosis. LDH is elevated; uric acid is high. Bone marrow aspirate is 'dry'; core biopsy shows hypercellular marrow with grade 3 reticulin fibrosis and atypical megakaryocytic clusters. Cytogenetics: new complex karyotype with monosomy 7. Which is the most appropriate next step in disease-directed management?", "options": ["Escalate hydroxyurea dose and add low-dose aspirin", "Start ruxolitinib and defer further planning until spleen size stabilizes", "Proceed to allogeneic hematopoietic stem cell transplantation evaluation", "Begin azacitidine as first-line therapy for post-PV myelofibrosis", "Initiate weekly pegylated interferon alfa-2a for cytoreduction"], "answer": "C", "answer_index": 2, "explanation": "She has post-polycythemia vera myelofibrosis with symptomatic splenomegaly, cytopenias, leukoerythroblastosis, and high-risk features (complex karyotype, monosomy 7), making allogeneic stem cell transplantation the only curative option and the preferred strategy if eligible. Ruxolitinib improves symptoms and spleen size but is not curative; azacitidine and interferon are not standard first-line disease-modifying therapies in high-risk post-PV MF, and hydroxyurea escalation will not address progression.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict: Correct best. Key stem clues: JAK2+ PV treated with hydroxyurea, now with B symptoms, splenomegaly, cytopenias, leukoerythroblastosis, dry tap, grade 3 fibrosis, and high-risk cytogenetics (complex karyotype, monosomy 7). This defines high-risk post-PV myelofibrosis. The logical flow is clear: high-risk features in a transplant-eligible patient direct evaluation for allogeneic HSCT, the only potentially curative option. No contradictions or underspecification exist; eligibility for transplant is a standard implied consideration. Medical accuracy is sound, aligning with NCCN/ELN guidelines for high-risk MF. Minor nuance: while ruxolitinib is a first-line symptomatic agent, the high-risk features correctly prioritize transplant evaluation. Minimal fix: none required for a board-style item; optionally, add 'She is otherwise healthy and eligible for transplant' to preempt eligibility questions.\",\n  \"logical_false_reason\": \"T\",\n  \"logical_validity\": true,\n  \"medical_accuracy_score\":  \t\n  \"5\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best. Key stem clues: JAK2+ PV treated with hydroxyurea, now with B symptoms, splenomegaly, cytopenias, leukoerythroblastosis, dry tap, grade 3 fibrosis, and high-risk cytogenetics (complex karyotype, monosomy 7). This defines high-risk post-PV myelofibrosis. The logical flow is clear: high-risk features in a transplant-eligible patient direct evaluation for allogeneic HSCT, the only potentially curative option. No contradictions or underspecification exist; eligibility for transplant is a standard implied consideration. Medical accuracy is sound, aligning with NCCN/ELN guidelines for high-risk MF. Minor nuance: while ruxolitinib is a first-line symptomatic agent, the high-risk features correctly prioritize transplant evaluation. Minimal fix: none required for a board-style item; optionally, add 'She is otherwise healthy and eligible for transplant' to preempt eligibility questions.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-003", "question": "A 28-year-old G1P0 woman at 33 weeks' gestation presents to the ED with acute dyspnea, pleuritic chest pain, and near syncope. HR 132/min, BP 82/48 mm Hg, RR 30/min, SpO2 89% on 6 L nasal cannula. Bedside echo reveals a dilated RV with McConnell sign and septal flattening. CTA is unavailable; lower-extremity duplex is pending. She is consentable and has no contraindications to thrombolysis. Fetal heart tones are 150 bpm with moderate variability. Which management is most appropriate now?", "options": ["Systemic thrombolysis with weight-based alteplase bolus and infusion", "Urgent catheter-directed thrombolysis with reduced-dose alteplase", "Immediate transfer for surgical embolectomy with cardiopulmonary bypass", "Initiate high-dose unfractionated heparin and defer reperfusion until postpartum", "Administer tenecteplase as a single IV bolus followed by heparin"], "answer": "A", "answer_index": 0, "explanation": "She has high-risk (massive) pulmonary embolism with shock in late pregnancy; systemic thrombolysis is recommended when no absolute contraindications exist, as maternal survival takes priority and pregnancy is only a relative contraindication. Catheter-directed therapy or surgical embolectomy may be considered when thrombolysis is contraindicated or fails, not as first-line; deferring reperfusion is unsafe, and tenecteplase bolus lacks robust pregnancy-specific safety and dosing data compared with standard alteplase protocols.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed. Key stem clues: 33 weeks pregnant, massive PE with shock (hypotension, RV strain), no absolute contraindications. Main logical issue: The keyed answer (A) is not the single best answer; current guidelines (ACCP, AHA) recommend systemic thrombolysis for massive PE with shock, but in pregnancy, the preferred agent is weight-based unfractionated heparin (option D) as initial therapy, with thrombolysis reserved for refractory cases. Option D is defensible as first-line, and option A is not guideline-supported as first choice in this scenario, creating a miskey. Main medical accuracy issue: Recommending systemic thrombolysis as first-line in a pregnant patient with shock oversimplifies guideline nuance. Minimal fix: Change key to D and adjust rationale to reflect guideline-concordant initial heparin therapy for massive PE in pregnancy, with thrombolysis as rescue.\",\n  \"logical_false_reason\": \"K\",\n  \"logical_validity\": false,\n  \"medical_accuracy_score\":  \"2\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed. Key stem clues: 33 weeks pregnant, massive PE with shock (hypotension, RV strain), no absolute contraindications. Main logical issue: The keyed answer (A) is not the single best answer; current guidelines (ACCP, AHA) recommend systemic thrombolysis for massive PE with shock, but in pregnancy, the preferred agent is weight-based unfractionated heparin (option D) as initial therapy, with thrombolysis reserved for refractory cases. Option D is defensible as first-line, and option A is not guideline-supported as first choice in this scenario, creating a miskey. Main medical accuracy issue: Recommending systemic thrombolysis as first-line in a pregnant patient with shock oversimplifies guideline nuance. Minimal fix: Change key to D and adjust rationale to reflect guideline-concordant initial heparin therapy for massive PE in pregnancy, with thrombolysis as rescue.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-004", "question": "A 4-year-old boy is brought to the PICU with progressive leg weakness and refusal to walk for 5 days after a viral upper respiratory infection. Exam: flaccid symmetric weakness in legs > arms, areflexia, intact sensation, no bowel/bladder dysfunction, and no cranial nerve involvement. He can lift his head briefly but cannot stand; FVC is 55% predicted. MRI spine is normal. CSF shows protein 42 mg/dL, 3 WBC/µL. Nerve conduction studies show reduced CMAP amplitudes with preserved conduction velocities and distal latencies; sensory studies are normal, and F-waves are absent. Which subtype best describes his neuropathy and has implications for prognosis and treatment response?", "options": ["Acute inflammatory demyelinating polyradiculoneuropathy (AIDP)", "Acute motor axonal neuropathy (AMAN) variant of Guillain-Barré syndrome", "Acute motor and sensory axonal neuropathy (AMSAN)", "Miller Fisher syndrome", "Acute flaccid myelitis related to enterovirus D68"], "answer": "B", "answer_index": 1, "explanation": "Normal conduction velocities with low CMAP amplitudes, preserved sensory responses, and absent F-waves indicate a purely motor axonal process, characteristic of AMAN, which in children often follows infection and may have rapid progression but good recovery with immunotherapy. AIDP would show demyelinating features (slowed velocities, prolonged latencies), AMSAN would have sensory involvement, Miller Fisher presents with ophthalmoplegia/ataxia, and acute flaccid myelitis involves spinal gray matter with MRI abnormalities and asymmetric weakness.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: K. Verdict on keyed answer: Miskeyed. The stem describes a child with acute flaccid symmetric weakness, areflexia, normal sensation, and CSF albuminocytologic dissociation, classic for Guillain-Barré syndrome (GBS). The electrophysiology shows reduced CMAP amplitudes with preserved velocities and normal sensory studies, which is most consistent with a primary axonal motor process. However, the absence of F-waves is a demyelinating feature, not typical for pure AMAN, which usually has preserved or only mildly abnormal F-waves. This creates a mixed picture. The keyed answer is AMAN (B), but the absent F-waves make Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP, A) also highly defensible, as AIDP can present with low CMAPs early on and absent F-waves are a hallmark. This is a case of M (multiple defensible) leading to K (miskeyed). The main logical issue is the electrophysiologic description is ambiguous between early AIDP and AMAN. Minimal fix: Change the nerve study description to clearly show features exclusive to AMAN (e.g., 'normal or minimally prolonged F-wave latencies').\",\n  \"logical_false_reason\": \"K\",\n  \"logical_validity\": false,\n  \"medical_accuracy_score\":  \"4\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K. Verdict on keyed answer: Miskeyed. The stem describes a child with acute flaccid symmetric weakness, areflexia, normal sensation, and CSF albuminocytologic dissociation, classic for Guillain-Barré syndrome (GBS). The electrophysiology shows reduced CMAP amplitudes with preserved velocities and normal sensory studies, which is most consistent with a primary axonal motor process. However, the absence of F-waves is a demyelinating feature, not typical for pure AMAN, which usually has preserved or only mildly abnormal F-waves. This creates a mixed picture. The keyed answer is AMAN (B), but the absent F-waves make Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP, A) also highly defensible, as AIDP can present with low CMAPs early on and absent F-waves are a hallmark. This is a case of M (multiple defensible) leading to K (miskeyed). The main logical issue is the electrophysiologic description is ambiguous between early AIDP and AMAN. Minimal fix: Change the nerve study description to clearly show features exclusive to AMAN (e.g., 'normal or minimally prolonged F-wave latencies').", "medical_accuracy_score": 4, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-005", "question": "A 47-year-old man with poorly controlled type 2 diabetes and daily alcohol use presents with 10 days of fever, right-sided headache, and progressive confusion. He was treated with oral amoxicillin-clavulanate for presumed sinusitis without improvement. On exam he is disoriented, febrile (38.8°C), with mild left hemiparesis and papilledema. CT head with contrast shows a 3.5-cm ring-enhancing lesion in the right frontal lobe with extensive surrounding edema contiguous with opacified frontal sinus. Emergent dexamethasone and broad-spectrum IV antibiotics are started. Neurocritical care team plans operative management. Which surgical approach is most appropriate now?", "options": ["CT-guided stereotactic needle aspiration of the abscess", "Open craniotomy with complete abscess excision and sinus drainage", "Endoscopic transnasal drainage of the frontal sinus only", "Placement of an external ventricular drain for CSF diversion and observation", "Delay surgical intervention; continue maximal medical therapy for 2 weeks"], "answer": "B", "answer_index": 1, "explanation": "A large frontal lobe abscess contiguous with frontal sinus and mass effect in an immunocompromised host favors open craniotomy with abscess excision plus definitive sinus drainage to eradicate the source and relieve mass effect. Needle aspiration alone risks persistent infection from ongoing sinus seeding; sinus drainage only is insufficient; EVD does not address the mass; delaying surgery risks herniation and neurological decline.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict: Correct best. Key stem clues: large (3.5 cm) ring-enhancing frontal lobe abscess with extensive edema and mass effect (papilledema, hemiparesis), contiguous with opacified frontal sinus, in an immunocompromised host (poorly controlled diabetes, alcohol use), and failure of prior antibiotics. This supports urgent surgical source control and mass relief. Main logical issue: None. Main medical accuracy issue: None; the keyed answer aligns with guidelines for large, symptomatic abscesses with mass effect and contiguous sinus source. Minimal fix: None required for validity; could specify 'significant mass effect' to further emphasize urgency over option A.\",\n  \"logical_false_reason\": \"T\",\n  \"logical_validity\": true,\n  \"medical_accuracy_score\":  \t\n  \"5\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best. Key stem clues: large (3.5 cm) ring-enhancing frontal lobe abscess with extensive edema and mass effect (papilledema, hemiparesis), contiguous with opacified frontal sinus, in an immunocompromised host (poorly controlled diabetes, alcohol use), and failure of prior antibiotics. This supports urgent surgical source control and mass relief. Main logical issue: None. Main medical accuracy issue: None; the keyed answer aligns with guidelines for large, symptomatic abscesses with mass effect and contiguous sinus source. Minimal fix: None required for validity; could specify 'significant mass effect' to further emphasize urgency over option A.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-006", "question": "A 66-year-old man with COPD and metastatic non-small cell lung cancer (PD-L1 80%) started pembrolizumab 10 weeks ago. He presents with 4 days of worsening exertional dyspnea and dry cough, afebrile, with O2 saturation 90% on room air. CT pulmonary angiography shows no embolus but reveals new bilateral, patchy ground-glass opacities and reticular changes in the lower lobes with subpleural sparing. There is no infection on extensive workup, BNP is normal, and no cardiac ischemia. He is on no new drugs besides pembrolizumab. How should this complication be graded and managed now?", "options": ["Grade 1 pneumonitis; continue pembrolizumab with close monitoring only", "Grade 2 pneumonitis; hold pembrolizumab and start prednisone 0.5 mg/kg/day", "Grade 2 pneumonitis; hold pembrolizumab and start prednisone 1-2 mg/kg/day", "Grade 3 pneumonitis; permanently discontinue pembrolizumab and give IV methylprednisolone 1-2 mg/kg/day", "Grade 3 pneumonitis; permanently discontinue pembrolizumab and give infliximab immediately without steroids"], "answer": "C", "answer_index": 2, "explanation": "He has symptomatic but non-life-threatening immune-related pneumonitis (dyspnea, new infiltrates, no severe hypoxia), corresponding to grade 2; standard management is to hold the checkpoint inhibitor and start systemic steroids at 1-2 mg/kg/day with a prolonged taper. Grade 3 would involve severe symptoms or oxygen requirement; lower steroid doses or continuation of pembrolizumab are inadequate, and infliximab is reserved for steroid-refractory cases, not first-line.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n    \"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed. Key stem clues: symptomatic pneumonitis (dyspnea, cough, O2 90% on RA, CT findings) without severe hypoxia or life-threatening features. This aligns with Grade 2 per CTCAE (symptomatic, medical intervention indicated, not interfering with ADL). The keyed answer (C) correctly identifies Grade 2 and holds pembrolizumab, but the steroid dose of 1-2 mg/kg/day is the guideline-recommended starting dose for Grade 2. However, option B also states Grade 2, holds pembrolizumab, and starts prednisone 0.5 mg/kg/day. Current major guidelines (ASCO, NCCN, drug label) recommend 1-2 mg/kg/day prednisone equivalent for Grade 2 pneumonitis. Therefore, option B's lower dose is subtherapeutic and incorrect, making C the unique best answer. The item is miskeyed only if one interprets the key as incorrect, but here the provided key (C) is correct. The logical issue is that both B and C are labeled Grade 2, but only C has the correct steroid dose, creating a potential for confusion, not a true miskey. The primary logical failure is actually M (Multiple answers defensible) if a test-taker assumes both B and C represent valid Grade 2 management, but guideline consensus makes C uniquely correct. Medical accuracy is sound. Minimal fix: Remove option B or change its steroid dose to an incorrect value (e.g., 0.1 mg/kg/day) to eliminate the near-identical Grade 2 distraction.\",\n    \"logical_false_reason\": \"M\",\n    \"logical_validity\": false,\n    \"medical_accuracy_score\":", "judge_output_valid": false, "judge_parse_error": "json decode error: Expecting value: line 5 column 30 (char 1533)"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-007", "question": "A 9-year-old girl presents with 2 weeks of progressive headache, morning vomiting, and decline in school performance. Exam reveals papilledema, dysmetria, and truncal ataxia. MRI brain shows an enhancing midline posterior fossa mass infiltrating the cerebellar vermis and roof of the fourth ventricle, with obstructive hydrocephalus. After CSF diversion and near-total resection, histology shows small round blue cells with Homer-Wright rosettes. Molecular profiling reveals WNT-activated medulloblastoma, CTNNB1 mutation, and monosomy 6; no metastatic disease on staging. Which adjuvant treatment strategy is most appropriate?", "options": ["Craniospinal irradiation at standard dose plus multi-agent chemotherapy (high-risk protocol)", "Focal posterior fossa irradiation only plus maintenance oral temozolomide", "Reduced-dose craniospinal irradiation with posterior fossa boost plus chemotherapy (standard-risk protocol)", "Observation only after gross total resection due to favorable WNT subtype", "High-dose chemotherapy with autologous stem cell rescue, without craniospinal irradiation"], "answer": "C", "answer_index": 2, "explanation": "WNT-activated medulloblastoma in a child with non-metastatic disease and near-total resection is standard-risk; current practice uses reduced-dose craniospinal irradiation with posterior fossa boost plus multi-agent chemotherapy to maintain excellent survival while reducing late toxicity. Standard-dose/high-risk protocols are unnecessary; focal RT alone or observation is inadequate due to CSF dissemination risk; high-dose chemo without CSI is investigational and not standard in this scenario.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n    \"analysis\": \"Validity label: V. Verdict: Correct best. Key stem clues: WNT-activated medulloblastoma, non-metastatic disease, near-total resection, and favorable molecular features (CTNNB1 mutation, monosomy 6). This defines a standard-risk patient. The logical flow is valid; the stem provides all necessary details (histology, molecular profile, staging, extent of resection) to select the standard-risk protocol. No contradictions or missing critical details. Medical accuracy is high, aligning with current consensus that standard-risk WNT medulloblastoma receives reduced-dose craniospinal irradiation with a boost and chemotherapy. Minor fix: Clarify 'near-total resection' as 'gross total or near-total resection' to align precisely with standard-risk criteria, though the intent is clear.\",\n    \"logical_false_reason\": \"T\",\n    \"logical_validity\": true,\n    \"medical_accuracy_score\":  \t\n  \"4\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best. Key stem clues: WNT-activated medulloblastoma, non-metastatic disease, near-total resection, and favorable molecular features (CTNNB1 mutation, monosomy 6). This defines a standard-risk patient. The logical flow is valid; the stem provides all necessary details (histology, molecular profile, staging, extent of resection) to select the standard-risk protocol. No contradictions or missing critical details. Medical accuracy is high, aligning with current consensus that standard-risk WNT medulloblastoma receives reduced-dose craniospinal irradiation with a boost and chemotherapy. Minor fix: Clarify 'near-total resection' as 'gross total or near-total resection' to align precisely with standard-risk criteria, though the intent is clear.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-008", "question": "A 71-year-old woman with hypertension and atrial fibrillation on rivaroxaban is admitted with sudden onset aphasia and right hemiplegia. CT head is negative for hemorrhage; CTA shows left M1 occlusion. Last rivaroxaban dose was 3 hours ago. Labs: creatinine 0.9 mg/dL, normal platelets, INR 1.2, anti-factor Xa level (rivaroxaban-calibrated) 170 ng/mL. She arrives 70 minutes after symptom onset. You are in a center with neurointerventional capability and access to andexanet alfa and 4-factor PCC. What is the best acute reperfusion strategy?", "options": ["Administer IV alteplase followed by mechanical thrombectomy", "Administer andexanet alfa to reverse rivaroxaban, then give IV alteplase", "Proceed directly to mechanical thrombectomy without IV thrombolysis", "Give 4-factor PCC then IV alteplase to offset rivaroxaban effect", "Defer reperfusion therapy and manage with permissive hypertension alone"], "answer": "C", "answer_index": 2, "explanation": "Recent rivaroxaban ingestion with high anti-factor Xa level is a contraindication to IV alteplase, and reversal with andexanet or PCC before tPA is not recommended due to uncertain safety and lack of evidence. In patients with large-vessel occlusion on DOACs, direct mechanical thrombectomy is the preferred reperfusion strategy. Withholding reperfusion altogether is inappropriate given eligibility for thrombectomy.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n    \"analysis\": \"Validity label: V. Verdict: Correct best. Key stem clues: acute ischemic stroke with large-vessel occlusion (left M1), recent (3h) rivaroxaban dose with high anti-factor Xa level (170 ng/mL), CT negative for hemorrhage, and arrival within 70 minutes at a thrombectomy-capable center. The high anti-factor Xa level is a strong contraindication to IV alteplase, making direct mechanical thrombectomy (option C) the guideline-supported standard of care. Options involving reversal agents (B, D) or alteplase (A) are incorrect due to lack of evidence and safety concerns. Option E is inappropriate as the patient is eligible for thrombectomy. No logical contradictions or missing details prevent a unique best answer. Medical accuracy is high. Minimal fix: None required; the item is clear and accurate.\",\n    \"logical_false_reason\": \"T\",\n    \"logical_validity\": true,\n    \"medical_accuracy_score\":", "judge_output_valid": false, "judge_parse_error": "json decode error: Expecting value: line 5 column 30 (char 913)"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-009", "question": "A 22-year-old man with sickle cell disease (HbSS) presents with high fever, cough, and pleuritic chest pain. CXR shows new multilobar infiltrates; oxygen saturation is 93% on 2 L/min nasal cannula. Labs: Hgb 7.2 g/dL (baseline 8.5), WBC 18,000/µL, platelets 310,000/µL, reticulocyte count 12%. He is diagnosed with acute chest syndrome and started on broad-spectrum antibiotics, incentive spirometry, and simple transfusion to Hgb 9.5 g/dL. Over 24 hours, oxygen requirement increases to 8 L/min with SpO2 90%, and CXR shows progression to near-complete bilateral airspace opacification. Hgb is now 10.3 g/dL, and he is tachypneic but not yet intubated. Which is the most appropriate next step?", "options": ["Increase simple transfusions to target Hgb 12 g/dL for better oxygen-carrying capacity", "Initiate exchange transfusion targeting HbS <30%", "Start high-dose corticosteroids to reduce pulmonary inflammation", "Add therapeutic anticoagulation for presumed pulmonary embolism", "Intubate and initiate low tidal-volume ventilation, deferring transfusion changes"], "answer": "B", "answer_index": 1, "explanation": "Worsening hypoxemia, radiographic progression, and clinical deterioration despite initial simple transfusion indicate severe acute chest syndrome, for which exchange transfusion to rapidly lower HbS (<30%) is recommended. Further simple transfusion risks hyperviscosity; steroids are controversial and may increase rebound pain; empiric anticoagulation is not first-line without PE evidence; ventilation may be needed but does not replace disease-modifying exchange.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict: Correct best. Key stem clues: sickle cell disease (HbSS), acute chest syndrome with worsening hypoxemia and radiographic progression despite initial simple transfusion, Hgb now 10.3 g/dL. The clinical deterioration despite standard care (antibiotics, simple transfusion) defines severe acute chest syndrome, for which exchange transfusion to rapidly reduce HbS percentage is the established next step to improve oxygenation and reduce sickling. The logic is sound: further simple transfusion (A) risks hyperviscosity; steroids (C) are not first-line and carry risks; anticoagulation (D) is not indicated without evidence of PE; intubation (E) is supportive but does not address the underlying pathophysiology. No contradictions or missing critical details. Medical accuracy aligns with guidelines. Minimal fix: none required; item is clear and accurate.\",\n  \"logical_false_reason\": \"T\",\n  \"logical_validity\": true,\n  \"medical_accuracy_score\":  \t\n  \"5\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best. Key stem clues: sickle cell disease (HbSS), acute chest syndrome with worsening hypoxemia and radiographic progression despite initial simple transfusion, Hgb now 10.3 g/dL. The clinical deterioration despite standard care (antibiotics, simple transfusion) defines severe acute chest syndrome, for which exchange transfusion to rapidly reduce HbS percentage is the established next step to improve oxygenation and reduce sickling. The logic is sound: further simple transfusion (A) risks hyperviscosity; steroids (C) are not first-line and carry risks; anticoagulation (D) is not indicated without evidence of PE; intubation (E) is supportive but does not address the underlying pathophysiology. No contradictions or missing critical details. Medical accuracy aligns with guidelines. Minimal fix: none required; item is clear and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-010", "question": "A 58-year-old man with alcohol-related cirrhosis and portal hypertension is admitted with confusion and generalized tonic-clonic seizures. He has been on valproic acid for epilepsy for 5 years without prior complications. Medications include lactulose and spironolactone. Exam: asterixis, disorientation, jaundice, and mild ascites. Labs: Na 130 mmol/L, K 4.2 mmol/L, BUN 10 mg/dL, creatinine 0.7 mg/dL, AST 65 U/L, ALT 40 U/L, total bilirubin 3.8 mg/dL, INR 1.7, ammonia 96 µmol/L. Serum valproate level is therapeutic, but free valproate level is supratherapeutic; serum carnitine is low, and EEG shows triphasic waves without epileptiform activity. Which is the most appropriate antiseizure management strategy?", "options": ["Continue valproic acid but lower the dose and optimize lactulose therapy", "Discontinue valproic acid and start levetiracetam with IV L-carnitine supplementation", "Switch valproic acid to phenytoin with aggressive albumin replacement", "Add topiramate to valproic acid to improve seizure control", "Continue valproic acid and start rifaximin to reduce ammonia"], "answer": "B", "answer_index": 1, "explanation": "He has cirrhosis with hyperammonemic encephalopathy and high free valproate, consistent with valproate-induced hyperammonemic encephalopathy exacerbated by liver disease and carnitine deficiency; the best approach is to stop valproate, use a non-hepatically metabolized agent such as levetiracetam, and give IV L-carnitine. Dose reduction or adjuncts (lactulose, rifaximin) without discontinuing valproate will not adequately address toxicity; phenytoin is highly protein-bound and hepatically metabolized, and adding topiramate may worsen hyperammonemia.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n    \"analysis\": \"Validity label: V. Verdict: Correct best. Key stem clues: cirrhosis, hyperammonemic encephalopathy (confusion, asterixis, triphasic waves, ammonia 96 µmol/L), supratherapeutic free valproate, low carnitine, and active seizures. This constellation is classic for valproate-induced hyperammonemic encephalopathy (VHE) in liver disease. The keyed answer (B) correctly addresses all components: discontinuing the offending hepatically metabolized drug (valproate), switching to a renally excreted agent (levetiracetam), and providing carnitine replacement. Alternatives are inferior: continuing valproate (A, D, E) fails to remove the cause; phenytoin (C) is also hepatically metabolized and highly protein-bound, making it risky in this hypoalbuminemic, coagulopathic patient. No logical contradictions or missing critical details. Medical accuracy is sound, aligning with standard management of VHE. Minimal fix: none required; item is clear and accurate.\",\n    \"logical_false_reason\": \"T\",\n    \"logical_validity\": true,\n    \"medical_accuracy_score\":  \t\n  \"5\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best. Key stem clues: cirrhosis, hyperammonemic encephalopathy (confusion, asterixis, triphasic waves, ammonia 96 µmol/L), supratherapeutic free valproate, low carnitine, and active seizures. This constellation is classic for valproate-induced hyperammonemic encephalopathy (VHE) in liver disease. The keyed answer (B) correctly addresses all components: discontinuing the offending hepatically metabolized drug (valproate), switching to a renally excreted agent (levetiracetam), and providing carnitine replacement. Alternatives are inferior: continuing valproate (A, D, E) fails to remove the cause; phenytoin (C) is also hepatically metabolized and highly protein-bound, making it risky in this hypoalbuminemic, coagulopathic patient. No logical contradictions or missing critical details. Medical accuracy is sound, aligning with standard management of VHE. Minimal fix: none required; item is clear and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]